Clinical trial register · Italy

Clinical Trials in Catania, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC

6778

Studies in scope

all four open statuses

4069

Recruiting now

open to new participants

1018

Lead sponsors

across recruiting studies

Top sites

Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967

Trials with a site in Catania

Status

Study

Lead sponsor

Phase

Enrol

Sites in Italy

Start

Not yet open

A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies

NCT07789015Idiopathic Inflammatory Myopathies

DrugNerandomilast

Boehringer Ingelheim

Phase 3

270

Bari, Catania, Padova, Pavia, Pisa, Torino

2026-11-09

Not yet open

Cefepime/Enmetazobactam for Bacteremic Complicated Urinary Tract Infections

NCT07725848Complicated Urinary Tract Infections, Antibiotic Resistance

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

200

Bologna, Catania, Milan

2026-10-15

Recruiting

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

NCT07559175Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality, Pancreatic Diseases

DrugZenpep

Aimmune Nestlé Health Science US R&D, LLC

Phase 2

Catania, Rozzano, Messina, Florence, Milan, Roma

2026-10

Recruiting

FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression

NCT07540988Interstitial Lung Diseases

DrugNerandomilast

Boehringer Ingelheim

Phase 3

466

Catania, Foggia, Forlì, Milan, Monza, Padova, Roma

2026-09-17

Recruiting

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

NCT07648264Secondary Immune Deficiency

DrugHizentra

CSL Behring

Phase 3

Rome, Brescia, Varese, Candiolo, Catania, Florence, Milan

2026-09-15

Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT07623161Myelofibrosis, Anemia

DrugElritercept

Takeda

Phase 3

324

Bologna, Cona, Meldola, Rome, Milan, Ancona, Catania, Florence

2026-09-10

Recruiting

A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

NCT07623200Essential Thrombocythemia

DrugINCA033989

Incyte Corporation

Phase 3

426

Bari, Bergamo, Bologna, Catania, Florence, Genova, Meldola, Milan

2026-09-08

Not yet open

Chemokine Receptors on CD8+ T Cells in Patients With Bipolar Disorder

NCT07785167Bipolar Affective Disorders

University of Catania

Observational

172

Catania

2026-09-07

Not yet open

Non-Coding RNAs Gene Expression in Psychiatric Disorders

NCT07649993Schizophrenia Disorders, Major Depression, Bipolar Affective Disorders, Obsessive Compulsive Disorder (OCD)

Carmen Concerto

Observational

384

Catania, Enna, Messina, Palermo

2026-09-01

Not yet open

triPle Oral thERapy With Bempedoic Acid vs uSual Care in Early Lipid Management of Patients With acUte coronAry synDromE

NCT07440381Acute Coronary Syndromes, Secondary Prevention, Lipids

Heart Care Foundation

Phase 3

600

Acquaviva delle Fonti, Altamura, Arezzo, Avellino, Bari, Casale Monferrato, Caserta, Catania

2026-09

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Alessandria, Bari, Bologna, Catania, Chieri, Cinisello Balsamo, Cosenza, Eboli

2026-08-21

Recruiting

PET Guided Dose Reduction for InvOlved Site Radiotherapy In Early sTage Unfavourable Hodgkin Lymphoma

NCT07256158Hodgkin Lymphoma

Fondazione Italiana Linfomi - ETS

Phase 3

518

Alessandria, Avellino, Aviano, Bergamo, Brescia, Cagliari, Candiolo, Catania

2026-07-10

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

Bologna, Catania, Chieti, Florence, Latina, Milan, Pisa, Ravenna

2026-06-29

Recruiting

Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.

NCT07333066Metastatic Hormone-sensitive Prostate Cancer

DrugsApalutamide (Erleada)·Docetaxel

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Phase 3

320

Catania, Foggia, Milan, Roma

2026-06-05

Not yet open

Olfactory and Trigeminal Functions in Patients With Multiple Sclerosis: Case-control Study

NCT06020937Multiple Sclerosis

University of Catania

Observational

200

Catania

2026-05-30

By invitation

A Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec

NCT07632404Diabetes Mellitus, Type 2

DrugInsulin icodec

Novo Nordisk A/S

Observational

214

Pescara, San Giovanni in Fiore (CS), Marano Di Napoli (NA), Rome, Milan, Cuneo, Catania, Bolzano

2026-05-28

Recruiting

Effect of High Flow Nasal Therapy (HFNC) Weaning Protocols vs Standard of Care on Respiratory Outcomes in Patients With Acute Respiratory Failure

NCT07638293Acute Respiratory Failure (ARF)

University of Milan

Not applicable

148

Milan, Catania

2026-05-15

Recruiting

Auditory Functions in Patients With Multiple Sclerosis

NCT06164483Multiple Sclerosis, Hearing Disorders

University of Catania

Observational

Catania

2026-05-11

Recruiting

Impact of Non-surgical Periodontal Treatment on Targeted Metabolomics

NCT07740447Periodontitis

University of Catania

Not applicable

Catania

2026-05-04

Recruiting

Periodontitis on Gingival Crevicular Fluid Metobolomics

NCT07739732Periodontitis

University of Catania

Observational

Catania

2026-05-04

Recruiting

Mitigation of Health Effects in Pregnant Women by Reducing Exposure to Heat and Air Pollution

NCT07609433Sleep Quality

University of Cyprus

Not applicable

102

Catania

2026-05-01

Recruiting

Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

NCT07447648Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography

Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Observational

Caserta, Catania, Cinisello Balsamo, Florence, Naples, Padova, Palermo, Roma

2026-04-30

Recruiting

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

NCT07287670Diffuse Cutaneous Systemic Sclerosis

Mediar Therapeutics

Phase 2

Ancona, Catania, Genoa, Milan, Modena, Roma

2026-04-16

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Brescia, Catania, Ferrara, Florence, Milan, Padova, Pisa, Roma

2026-04-13

Recruiting

Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis

NCT07474831Recurrent Bacterial Vaginosis

Liaquat University of Medical & Health Sciences

Not applicable

132

Forlì, Ravenna, Rome, Brescia, Pavia, Turin, Catania, Florence

2026-03-23

Recruiting

ROMANCE: "Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer"

NCT07381764Metastatic Colorectal Cancer (CRC)

DrugsErbitux·Trifluridine/Tipiracil·Cetuximab·Irinotecan

Gruppo Oncologico Italia Meridionale

Phase 2

150

Alessandria, Ancona, Aviano, Caserta, Castellana Grotte, Catania, Catanzaro, Florence

2026-03-20

Recruiting

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

NCT07361510Non-Small Cell Lung Cancer (NSCLC)

DrugsPumitamig·Pembrolizumab

Bristol-Myers Squibb

Phase 3

750

Ferrara (Cona), Aviano, Catania, Candiolo, Genova, Milan, Naples, Novara

2026-03-12

Recruiting

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849CRC (Colorectal Cancer)

DrugsINCA33890·Folfox·Bevacizumab

Incyte Corporation

Phase 3

700

Ancona, Aviano, Bari, Brescia, Candiolo, Catania, Milan, Naples

2026-03-05

Recruiting

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

NCT07438496Lupus Erythematosus, Systemic

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

600

Ancona, Catania, Milan, Perugia, Roma, Rozzano, Torino, Udine

2026-03-05

Recruiting

Poland-Italy Aortic Research Bridge Real World Registry

NCT07476196Abdominal Aortic Aneurysm

American Heart of Poland

Observational

200

Castel Volturno, Catania, Pozzilli, Reggio Emilia, San Donato Milanese

2026-03-01

Recruiting

Outcomes in ARMs: Comparison Between Surgical Techniques in Patients With Perineal or Vestibular Fistula - a Multicenter Italian Study

NCT07438691Anorectal Malformations

Meyer Children's Hospital IRCCS

Observational

500

Florence, Bergamo, Brescia, Catania, Lecce, Modena, Novara, Padova

2026-02-05

Not yet open

PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

NCT07207785Mantle Cell Lymphoma

DrugPirtobrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Meldola, Rozzano, Ancona, Avellino, Biella, Bologna, Brescia, Catania

2026-02-01

Not yet open

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

NCT07381777Locally Advanced Rectal Cancer (LARC)

DrugsXelox·Dostarlimab

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2

270

Arezzo, Aviano, Bologna, Brescia, Catania, Cuneo, Florence, Genova

2026-01-31

Recruiting

Targeting Real World Usage In Stroke Treatment

NCT07474935Saccular and Fusiform Aneurysms, Pseudoaneurysm, Vascular Dissection, Perforation

Phenox GmbH

Observational

5,000

Catania, Milan, Naples

2026-01-29

Recruiting

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07216703Cervical Cancer

DrugsMvasi·Sacituzumab tirumotecan·Paraplatin·Avastin

Merck Sharp & Dohme LLC

Phase 3

1,023

Meldola, Aviano, Milan, Brescia, Catania, Padova, Roma, Torino

2026-01-19

Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480Multiple Myeloma, Secondary Immunodeficiency

Takeda

Phase 3

183

Catania, Pavia, Pescara, Roma, Torrette

2026-01-14

Recruiting

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT07179380Pulmonary Hypertension, Interstitial Lung Disease

DrugTreprostinil Palmitil

Insmed Incorporated

Phase 3

344

Bologna, Catania, Milan, Modena, Monza, Naples, Pavia, Roma

2026-01-07

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

Brescia, Catania, Florence, Lecco, Milan, Naples, Parma, Pisa

2025-12-29

Active, closed

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

NCT07128199Lung Cancer, Adjuvant, Post-surgical, EGFR

DrugZipalertinib

Taiho Oncology, Inc.

Phase 3

360

Alessandria, Ancona, Bergamo, Bologna, Catania, Meldola, Livorno, Legnano

2025-12-22

Active, closed

WATCHMAN FLX Pro European Registry

NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure

Boston Scientific Corporation

Observational

189

Catania, Milan, Verona

2025-12-17

Recruiting

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

NCT07155187Non-Small Cell Lung Cancer, c-MET

DrugsTelisotuzumab Adizutecan·Osimertinib

AbbVie

Phase 2/3

490

Milan, Monza, Fano, Aviano, Rome, Candiolo, Catania, Verona

2025-12-10

Recruiting

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

110

Catania, Padova, Rome

2025-12-04

Recruiting

RandomIsed sTudy of Physiologic cArdiac stimuLation in patIents With Atrio-ventricular Conduction Disease

NCT07279870Atrioventricular Block

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Not applicable

1,260

Bari, Bologna, Catania, Ferrara, Milan, Novara, Palermo, Parma

2025-12-03

Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

NCT07230691Carcinoma, Non-Small-Cell Lung

Janssen Research & Development, LLC

Observational

380

Avellino, Aviano, Bari, Bergamo, Brescia, Candiolo, Catania, Catanzaro

2025-12-03

Recruiting

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo

NCT06804811NonSegmental Vitiligo

DrugRuxolitinib

Incyte Corporation

Phase 3

250

Bologna, Brescia, Catania, Milan, Naples, Padua, Roma, Rome

2025-11-13

Recruiting

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

NCT07170917Hidradenitis Suppurativa

DrugBrivekimig

Sanofi

Phase 2

208

Milan, Catania, Roma

2025-11-06

Recruiting

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

NCT07213804Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Neoplasm Metastasis

DrugsSofe-M·MIRV·Pegylated liposomal doxorubicin·Topotecan

Eli Lilly and Company

Phase 3

1,630

Bologna, Catania, Lecce, Lucca, Milan, Modena, Naples, Prato

2025-10-22

Recruiting

Post Authorization Efficacy and Safety Study (PAES) to Confirm and Collect More Clinical Data of Buccalin® Tablets In the Prophylaxis of Recurrent Lower Respiratory Tract Infections (RLRTIs).

NCT06736288Respiratory Infection, Lower Respiratory Tract Infection (LRTI)

Laboratorio Farmaceutico SIT srl

Phase 4

240

Alessandria, Catania, Milan, Roma, Sassari

2025-10-21

Recruiting

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Stemline Therapeutics, Inc.

Observational

140

Alessandria, Bari, Bologna, Brescia, Catania, Florence, Milan, Naples

2025-10-17

Recruiting

Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

NCT07389265Metastatic Colorectal Cancer (mCRC)

DrugsFOLFOX (Folinic acid·Erbitux·Folfox·Fluorouracil

University of Campania Luigi Vanvitelli

Phase 3

480

Ancona, Avellino, Aviano, Bari, Brescia, Castellana Grotte, Catania, Catanzaro

2025-10-01

Recruiting

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

200

Bologna, Catania, Milan, Padova, Roma, Salerno

2025-09-30

Recruiting

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT07111520Non-small Cell Lung Cancer

DrugsBNT326·Pumitamig

BioNTech SE

Phase 1/2

880

Alessandria, Catania, Florence, Milan, Roma

2025-09-22

Recruiting

Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®

NCT07206628Adherence to Glaucoma Therapy

Laboratoires Thea

Observational

200

Bologna, Catania, Corigliano, Genova, Lecce, Lucca, Modena, Morrovalle

2025-09-19

Not yet open

Microbiological and Clinical Characteristics of Severe Infections Caused by Carbapenem-Resistant Enterobacterales

NCT07160569Carbapenem-Resistant Enterobacteriaceae Infection

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

100

Rome, Catania, Catanzaro, Reggio Calabria

2025-09-01

Not yet open

Long-term Assessment of Chlormethine Gel in Mycosis Fungoides

NCT07046663Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Fondazione Italiana Linfomi - ETS

Observational

190

Ancona, Bergamo, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-09

Not yet open

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

NCT07124884Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer

Federation Francophone de Cancerologie Digestive

Phase 2

300

Aviano, Catania, Florence, Livorno, Meldola, Milan, Monserrato, Padova

2025-08-31

Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06948318Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

150

Naples, Rome, Catania, Bologna, Milan, Monza, Novara, Torino

2025-08-14

By invitation

Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)

NCT06898086Severe Aortic Stenosis

Rede Optimus Hospitalar SA

Not applicable

620

Palermo, Pisa, Catania, Mestre, Roma, Siena, Trieste

2025-08-08

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

NCT07098338Non-Small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

278

Aviano, Catania, Meldola, Milan, Orbassano, Roma, Rozzano

2025-08-07

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Alessandria, Aviano, Bari, Bologna, Catania, Florence, Haifa, Milan

2025-08-01

Active, closed

A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata

NCT07029711Severe Alopecia Areata

DrugsRitlecitinib higher·Ritlecitinib lower

Pfizer

Phase 3

208

Bologna, Brescia, Catania

2025-07-31

Recruiting

Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer

NCT07093801Metastatic Castration Resistant Prostate Cancer

Novartis Pharmaceuticals

Observational

300

Alessandria, Asti, Bergamo, Brescia, Catania, Meldola, Cona, Foggia

2025-07-30

Recruiting

A Muscle-brain Interplay Study in Neurological Disorders

NCT07477821Neurological Disorders, Health Adult Subjects

Istituti Clinici Scientifici Maugeri SpA

Observational

150

Catania, Messina, Milan, Roma

2025-07-24

Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)

DrugsSigvotatug vedotin·Pembrolizumab

Pfizer

Phase 3

714

Naples, Misterbianco, Meldola, Pesaro (PU), Orbassano, Rome, Roma, Catania

2025-07-23

Recruiting

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases

DrugsVicadrostat·Dapagliflozin

Boehringer Ingelheim

Phase 3

11,800

Acquaviva Delle Fonti (BA), Bergamo, Brescia, Catania, Catanzaro, Chieti, Cona (FE), Coppito (AQ)

2025-07-22

Active, closed

A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG

NCT06892288Phosphomannomutase 2 Deficiency, PMM2-CDG

Glycomine, Inc.

Phase 2/3

Catania, Pisa

2025-07-09

Active, closed

Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

NCT06979531Primary Sjögren's Syndrome

DrugIMVT-1402

Immunovant Sciences GmbH

Phase 2

180

Catania, Milan, Palermo, Perugia, Rome

2025-06-30

By invitation

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07007637Hidradenitis Suppurativa

DrugSonelokimab

MoonLake Immunotherapeutics AG

Phase 3

835

Catania, Chieti, Cona, Florence, Milan, Modena, Naples, Perugia

2025-06-27

Recruiting

Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

NCT06961214Pulmonary Disease, Chronic Obstructive

DrugDepemokimab

GlaxoSmithKline

Phase 3

961

Castelvenere, Foggia, Roma, Catania, Ferrara, Genova, Rozzano

2025-06-23

Active, closed

Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)

NCT06959225Hidradenitis Suppurativa

DrugRuxolitinib

Incyte Corporation

Phase 3

580

Catania, Cona, Florence, Milan, Naples, Roma, Rozzano, Torino

2025-06-23

Active, closed

A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis

NCT06832618Atopic Dermatitis

DrugRuxolitinib

Incyte Corporation

Phase 3

159

Catania, Milan, Naples, Padova, Rome

2025-06-17

Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

NCT06943872Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

DrugsSonrotoclax·Venclexta·Obinutuzumab·Venetoclax

BeOne Medicines

Phase 3

630

Bari, Cagliari, Catania, Ferrara, Milan, Modena, Pagani

2025-06-11

Recruiting

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568Endometrial Cancer

DrugsDoxorubicin·Docetaxel·Paclitaxel

BioNTech SE

Phase 3

480

Bari, Bologna, Catania, Meldola, Milan, Naples, Roma, Torino

2025-06-10

Recruiting

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

NCT06872892Bronchiectasis

DrugVerducatib

Boehringer Ingelheim

Phase 3

1,755

Ancona, Bologna, Catania, Genova, Messina, Milan, Monza (MB), Naples

2025-06-09

Recruiting

A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome

NCT06847867Myelodysplastic Syndromes

DrugMomelotinib

GlaxoSmithKline

Phase 2

Udine, Catania, Florence, Milan, Orbassano to, Rozzano MI

2025-06-05

Active, closed

A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

NCT06821542Chronic Graft-versus-host-disease

DrugAxatilimab

Incyte Corporation

Phase 3

Alessandria, Ancona, Bergamo, Bologna, Brescia, Catania, Florence, Genova

2025-06-04

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

Altamura, Arzignano, Bergamo, Bologna, Brescia, Caserta, Catania, Cona

2025-06-04

Not yet open

The Treatment Burden of Myopic Choroidal Neovascularization

NCT07009574Myopic Choroidal Neovascularisation, Anti-VEGF Treatment, Burden

Policlinico Gaspare Rodolico - San Marco Catania

Observational

100

Catania

2025-06-01

Recruiting

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504Endometrial Cancer

DrugsSacituzumab tirumotecan·Docetaxel·Keytruda·Paclitaxel

Merck Sharp & Dohme LLC

Phase 3

1,123

Meldola, Milan, Catania, Florence, Naples, Pisa, Roma, Torino

2025-05-22

Active, closed

Long-term Study Evaluating Joint Health in People With Haemophilia A Receiving Real-world Prophylactic Treatment With Efanesoctocog Alfa

NCT06940830Hemophilia A

DrugEfanesoctocog alfa

Swedish Orphan Biovitrum

Phase 4

252

Catania, Padua, Salerno, Turin

2025-05-21

Recruiting

Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma

NCT06588205Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

Fondazione Italiana Linfomi - ETS

Observational

200

Alessandria, Ancona, Bari, Brescia, Candiolo, Castelfranco Veneto, Catania, Civitanova Marche

2025-05-05

Recruiting

Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI)

NCT06965023ST-elevation Myocardial Infarction (STEMI), Microplastics, Nanoplastics, Pollution Exposure

Azienda Ospedaliera "Sant'Andrea"

Observational

130

Roma, Caserta, Catania, Ferrara, Forlì, Milan, Naples, Turin

2025-04-22

Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer

DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab

Corcept Therapeutics

Phase 2

270

Catania, Milan, Pavia, Rome, Torino, Treviso

2025-04-11

Recruiting

BRCA Mutation Carriers' Platform a Multicenter Study

NCT07253051BRCA1 Mutation, BRCA2 Mutation

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

10,000

Avellino, Aviano, Bari, Bergamo, Catania, Cuneo, Enna, Florence

2025-04-05

Active, closed

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

NCT06863961Atopic Dermatitis

DrugAfimkibart

Hoffmann-La Roche

Phase 2

162

Roma, Milan, Catania, Ancona

2025-04-01

Recruiting

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112Endometrial Cancer

DrugsRilvegostomig·Taxotere·Paraplatin·Trastuzumab deruxtecan

AstraZeneca

Phase 3

600

Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Roma, Rome

2025-03-27

Recruiting

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

NCT06890598Carcinoma, Non-Small-Cell Lung

DrugsOlomorasib·Durvalumab·Pembrolizumab

Eli Lilly and Company

Phase 3

700

Bari, Catania, Genova, Meldola, Milan, Monza, Naples, Orbassano

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Catania, Foggia, Genoa, Roma

2025-03-26

Recruiting

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

NCT06819007Ovarian Cancer

DrugsTrastuzumab deruxtecan·Bevacizumab

Daiichi Sankyo

Phase 3

582

Bari, Bologna, Catania, Milan, Monza, Naples, Pisa, Ponderano

2025-03-19

Recruiting

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

NCT07214324Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM)

Azienda USL Reggio Emilia - IRCCS

Observational

Bologna, Catania, Palermo, Reggio Emilia

2025-03-17

Active, closed

A Phase 2 in Adult Subjects With Hereditary Angioedema

NCT06846398Hereditary Angioedema (HAE)

DrugBW-20805

Shanghai Argo Biopharmaceutical Co., Ltd.

Phase 2

Catania, Florence, Padova

2025-02-28

Recruiting

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

NCT06855498Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

600

Bari, Brescia, Catania, Chieti, Florence, L’Aquila, Milan, Naples

2025-02-28

Recruiting

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

DrugsMomelotinib·Reblozyl·Luspatercept

GlaxoSmithKline

Phase 2

Bologna, Catania, Florence, Meldola FC, Milan, Roma

2025-02-28

Recruiting

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

NCT06731478Gastric Cancer, Gastroesophageal Junction Cancer

DrugsTrastuzumab deruxtecan·Trastuzumab·Keytruda·Pembrolizumab

Daiichi Sankyo

Phase 3

726

Catania, Florenze, Genova, Milan, Modena, Naples, Padova, Pisa

2025-02-27

Recruiting

Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

NCT06588868Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome

Fondazione Italiana Linfomi - ETS

Observational

400

Ancona, Bari, Bologna, Brescia, Cagliari, Catania, Florence, Genova

2025-02-27

Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

NCT06722235Immune Thrombocytopenic Purpura (ITP)

DrugMezagitamab

Takeda

Phase 3

171

Naples, Rome, Catania, Bologna, Milan, Monza, Novara, Torino

2025-02-27

Recruiting

Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.

NCT06869473Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer

Gruppo Oncologico del Nord-Ovest

Phase 2

Cagliari, Catania, Florence, Milan, Rozzano, Naples, Roma

2025-02-20

Recruiting

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

NCT06612268Sickle Cell Disease

DrugEtavopivat

Novo Nordisk A/S

Phase 3

510

Orbassano, Verona, Brescia, Catania, Modena, Monza, Naples, Padova

2025-02-17

Recruiting

Gonadic Function and Pubertal Development in Female Patients With Classic Galactosemia

NCT07461519Galactosemia

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Bologna, Bari, Cagliari, Catania, Catanzaro, Florence, Genova, Messina

2025-02-12

Active, closed

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

NCT06834360Chronic Rhinosinusitis With Nasal Polyps

DrugsItepekimab·Mometasone furoate

Sanofi

Phase 3

216

Milan, Naples, Catania

2025-02-06

Recruiting

An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

NCT06764693Psoriatic Arthritis

AbbVie

Observational

1,200

Rozzano, Milan, Naples, Rome, Ancona, Brescia, Campobasso, Catania

2025-01-31

Active, closed

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

NCT06799000Hidradenitis Suppurativa

DrugRemibrutinib

Novartis Pharmaceuticals

Phase 3

588

Ancona, Brescia, Catania, Cona, Florence, Rozzano, Modena, Pisa

2025-01-31

Recruiting

Landiolol in Mitral Valve Surgery

NCT06793670Cardiac Failure, Low Cardiac Output Syndrome

DrugLandiolol

Università Vita-Salute San Raffaele

Phase 4

1,500

Alessandria, Torino, Catania, Florence, Foggia, Genova, Milan, Palermo

2025-01-28

Recruiting

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

NCT06259929Breast Cancer

DrugsGiredestrant·Abemaciclib

Fondazione Oncotech

Phase 2

Catania, Genova, Naples, Padova, Aviano, Roma

2025-01-27

Recruiting

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

NCT06585774Chronic Graft-versus-host-disease

DrugsAxatilimab·Methylprednisolone·Prednisolone·Prednisone

Incyte Corporation

Phase 3

240

Alessandria, Ancona, Bari, Brescia, Catania, Genova, Milan, Naples

2025-01-21

Recruiting

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424Arthritis, Psoriatic

DrugIcotrokinra

Janssen Research & Development, LLC

Phase 3

750

Ancona, Brescia, Catania, Milan, Naples, Pavia, Roma, Rozzano

2025-01-09

Recruiting

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

NCT06712316Non-small Cell Lung Cancer

DrugsPumitamig·Pemetrexed·Paclitaxel·Carboplatin

BioNTech SE

Phase 2/3

1,580

Avellino, Aviano, Bologna, Candiolo, Catania, Cona, Cremona, Lucca

2025-01-07

Active, closed

A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)

NCT06660654Advanced Solid Tumor, Metastatic Solid Tumors

DrugR-DXd

Daiichi Sankyo

Phase 2

335

Catania, Genova, Meldola, Milan, Naples, Terni

2025-01-06

By invitation

Analysis of Line-Field Confocal Optical Coherence Tomography (LC-OCT) in Characterization of Gingival Systemic Health, Gingivitis and Periodontitis

NCT06831487Gingival Diseases

University of Catania

Not applicable

Catania

2025-01-02

Recruiting

Prehabilitation to Improve Heart Rate Variability (PRIME)

NCT06744413Cancer Surgery

Università Vita-Salute San Raffaele

Not applicable

600

Catania, Foggia, Milan, Pisa

2024-12-20

Recruiting

Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer in Italy

NCT06771193Cervical Cancer, Locally Advanced Cervical Cancer, Recurrent Cervical Cancer, Metastatic Cervical Cancer

MSD Italia S.r.l.

Observational

200

Bologna, Catania, Genova, Milan, Modena, Naples, Aviano, Roma

2024-12-17

Recruiting

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma

DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone

GlaxoSmithKline

Phase 3

520

Ancona, Catania, Meldola FC, Palermo, Pavia, Pisa, Roma

2024-12-16

Recruiting

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

NCT06750094Colorectal Neoplasms

DrugsLeucovorin calcium/Levoleucovorin·Amivantamab·Erbitux·Avastin

Janssen Research & Development, LLC

Phase 3

700

Candiolo, Catania, Florence, Milan, Padova, Pisa, Rozzano, Udine

2024-12-12

Recruiting

REdo Transcatheter Aortic VALVE Implantation for the Management of Transcatheter Aortic Valve Failure

NCT06557798Aortic Valve Stenosis

The Leeds Teaching Hospitals NHS Trust

Observational

550

Brescia, Catania, Genova, Milan, Palermo, San Donato Milanese, Torino, Verona

2024-12-12

Recruiting

Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

NCT06823960Marginal Zone Lymphoma(MZL)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Alessandria, Bologna, Catania, Cosenza, Ferrara, Meldola, Milan, Padova

2024-12-09

Active, closed

A Long-term Safety and Efficacy Study of N-Acetyl-GED-0507-34-LEVO Gel 5%, in Subjects With Acne Vulgaris (GEDACNE-LT)

NCT07389109Acne Vulgaris

PPM Services S.A.

Phase 3

400

Ancona, Florence, Genova, Parma, Pavia, Roma, Bologna, Catania

2024-12-05

By invitation

Effects of Enamel Matrix Derivative in the Treatment of Peri-implant Mucositis

NCT06725095Mucositis, Peri Implant Mucositis

University of Catania

Not applicable

Catania

2024-12-05

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Bologna, Catania, Florence, Padua, Pisa, Roma, Rozzano

2024-12-03

Recruiting

Stereotactic Body Radiotherapy (SBRT) for Reirradiation of Inoperable Lung Lesions

NCT07401615Non Small Cell Lung Cancer, Pulmonary Stereotactic Radiotherapy

Istituto Clinico Humanitas

Observational

150

Bergamo, Bologna, Catania, Milan, Rozzano, Naples, Roma, Venezia

2024-11-25

Active, closed

A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

NCT06422884Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease

DrugTaladegib

Endeavor Biomedicines, Inc.

Phase 2

213

Bologna, Padova, Florence, Catania, Milan, Turin

2024-11-15

Recruiting

FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

NCT06733038Colorectal Cancer

DrugsFluorouracil·Leucovorin·Irinotecan·Adrucil

Gruppo Oncologico del Nord-Ovest

Phase 3

238

Brescia, Catania, Meldola, San Giovanni Rotondo, Florence, Tricase, Livorno, Lucca

2024-11-15

Active, closed

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

NCT06492837Follicular Lymphoma

DrugsMosunetuzumab·Zanubrutinib

Fondazione Italiana Linfomi - ETS

Phase 2

Candiolo, Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Milan

2024-10-23

Active, closed

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

NCT06447168Primary Biliary Cholangitis

Ipsen

Observational

424

Bergamo, Catania, Florence, Milan, Novara, Roma

2024-10-14

Recruiting

Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813Myelofibrosis

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Observational

617

Alessandria, Bergamo, Bologna, Catania, Florence, Milan, Monza, Naples

2024-10-14

Active, closed

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

NCT06516952Prurigo Nodularis

DrugPovorcitinib

Incyte Corporation

Phase 3

349

Catania, Chieti, L’Aquila, Milan, Naples, Perugia, Pisa, Rome

2024-10-10

Active, closed

A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy

NCT06568237Multiple System Atrophy

DrugEmrusolmin

Teva Branded Pharmaceutical Products R&D LLC

Phase 2

349

Bologna, Catania, Milan, Padova, Roma, Salerno

2024-10-02

Recruiting

Development of a Natural Language Processing Tool to Enable Clinical Research in Emergency Medicine

NCT06240572Emergency Medicine

Mario Negri Institute for Pharmacological Research

Observational

300,000

Milan, Catania, Orbassano, Pozzuoli, Torino, Vercelli

2024-10-01

By invitation

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

NCT06657859Pmm2-CDG, Phosphomannomutase 2 Deficiency

Glycomine, Inc.

Phase 2

Catania, Pisa

2024-09-30

Recruiting

European Unified Registries for Heart Care Evaluation and Randomised Trials Italy

NCT07283809ACS - Acute Coronary Syndrome

Heart Care Foundation

Observational

5,000

Montevarchi, Acquaviva delle Fonti, Altamura, Bari, Brescia, Monserrato, Catania, Campobasso

2024-09-15

Recruiting

Measure of Outcomes in Patients With Advanced Ovarian Cancer According to Homologous Recombination Status and Matched Therapies in a Real-world Scenario

NCT06836219Ovarian Cancer

Consorzio Oncotech

Observational

300

Bari, Bologna, Cuneo, Catania, Meldola, Florence, Genova, Monza

2024-09-13

Recruiting

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150Non-cystic Fibrosis Bronchiectasis

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA

Phase 2

284

Bologna, Monza, Rozzano, Pavia, Catania

2024-09-11

Active, closed

Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

NCT06832371Homozygous Familial Hypercholesterolemia (HoFH), Major Adverse Cardiovascular Events (MACE), Dyslipidemia

Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

Observational

Catanzaro, Caserta, Naples, Bologna, Ferrara, Modena, Genova, Catania

2024-09-09

Recruiting

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis

DrugEfruxifermin

Akero Therapeutics, Inc

Phase 3

2,150

Foggia, San Giovanni Rotondo, Rozzano, Torino, Bologna, Catania, Messina, Milan

2024-09-04

Active, closed

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

NCT06550076Plaque Psoriasis

DrugZasocitinib

Takeda

Phase 3

2,099

Rozzano, Catania, Florence

2024-09-04

By invitation

Validation of a Multidimensional Scale for the Detection of Health Needs in People With HIV

NCT07077642HIV, Quality of Life

Giovanni Di Perri

Observational

200

Genova, Milan, Torino, Bari, Catania, Naples, Padova, Roma

2024-09-02

Recruiting

Multidimensional Omics Analysis in Malignant Pleural Mesothelioma

NCT07561190Malignant Pleural Mesothelioma (MPM)

Azienda USL Reggio Emilia - IRCCS

Observational

300

Catania, Naples, Reggio Emilia, Roma

2024-08-30

Recruiting

Rehabilitation With and Without Robot and Allied Digital Technologies in Stroke Patients

NCT06547827Stroke

Fondazione Don Carlo Gnocchi ETS

Not applicable

596

Acerenza, Bari, Bergamo, Catania, Catanzaro, Crotone, Foggia, Genova

2024-08-12

Active, closed

Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib

NCT06531109Alopecia Areata

DrugRitlecitinib

Pfizer

Observational

450

Bari, Rozzano, Bologna, Catania, Roma, Rome

2024-08-07

Recruiting

Peripheral Mononuclear Cells to Screen, Monitor and Stratify the Population at Risk of Osteoporosis and Fractures

NCT06551155Osteoporosis, Osteopenia, Osteoporosis Fracture

Istituto Ortopedico Rizzoli

Observational

120

Bologna, Catania

2024-08-05

Active, closed

Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension

NCT06492291Hypercholesterolemia

DrugsEnlicitide·Enlicitide Decanoate

Merck Sharp & Dohme LLC

Phase 3

3,000

Rome, Milan, Turin, Catania

2024-08-05

Active, closed

ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients

NCT06345157Multiple Sclerosis, Relapsing-Remitting

DrugOfatumumab

Novartis Pharmaceuticals

Observational

379

Ancona, L’Aquila, Bari, Bergamo, Chieti, Catania, Catanzaro, Cona

2024-07-30

Recruiting

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306Depressive Disorder, Major

DrugSeltorexant

Janssen Research & Development, LLC

Phase 3

752

Brescia, Catania, Chieti, Genova, Monza, Pisa, Roma, Salerno

2024-07-25

Active, closed

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT06459180Cervical Cancer

DrugsTisotumab Vedotin·Vinorelbine·Topotecan·Sacituzumab tirumotecan

Merck Sharp & Dohme LLC

Phase 3

686

Bologna, Milan, Monza, Rozzano, Turin, Brescia, Catania, Naples

2024-07-24

Recruiting

Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )

NCT07368582Pediatric Cancer, Pediatric Cancer Patients, Pediatric Oncology, Rehabilitation

Associazione Italiana Ematologia Oncologia Pediatrica

Observational

249

Bergamo, Bologna, Bolzano, Bosisio Parini, Brindisi, Catania, Conegliano, Florence

2024-07-19

Recruiting

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

NCT06979323Asthma

DrugDepemokimab

GlaxoSmithKline

Phase 3

150

Catania, Genova, Roma, Rozzano

2024-07-19

Recruiting

PK/PD Analysis of Ceftazidime/Avibactam or Cefiderocol With or Without Fosfomycin for the Treatment of Difficult To-treat Gram-negative Infections

NCT06651047Gram Negative Infection, Antimicrobial Resistance (AMR)

University of Bologna

Observational

120

Bologna, Catania, Milan, Padova, Palermo, Rome, Siena, Turin

2024-07-09

Recruiting

Respiratory Strategies in COPD Patients With Persistent Hypercapnia Following Exacerbation

NCT07065799COPD, Hypercapnia, Exacerbation Copd

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Not applicable

Arezzo, Bolzano, Catania, Pavia, Piacenza

2024-06-30

Active, closed

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228Hidradenitis Suppurativa

DrugLutikizumab

AbbVie

Phase 3

1,400

Cona, Florence, Rozzano, Naples, Rome, Catania, Milan

2024-06-27

Recruiting

A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

DrugTagraxofusp

Stemline Therapeutics, Inc.

Observational

Alessandria, Bologna, Catania, Cuneo, Ferrara, Florence, Genova, Milan

2024-06-26

Recruiting

A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced

NCT06467383Non-small Cell Lung Cancer, NSCLC, NSCLC, Stage III, NSCLC, Stage I

MSD Italia S.r.l.

Observational

600

San Giovanni Rotondo, Brescia, Campobasso, Catania, Florence, Genova, Messina, Milan

2024-06-25

Active, closed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549Moderate to Severe Plaque Psoriasis

DrugsBimekizumab·Ustekinumab

UCB Biopharma SRL

Phase 3

176

Ancona, Località Torrette, Catania, Pisa, Roma

2024-06-25

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

Ancona, Bari, Catania, Milan, Padova, Palermo, Pavia, Pisa

2024-06-20

Recruiting

Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma

NCT06749600Primary Ovarian Leiomyosarcoma

Azienda USL Reggio Emilia - IRCCS

Observational

Modena, Parma, Reggio Emilia, Avellino, Catania, Milan, Monza, Naples

2024-06-14

Active, closed

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT06082167Head and Neck Squamous Cell Carcinoma

DrugsZanzalintinib·Keytruda·Pembrolizumab

Exelixis

Phase 2/3

600

Candiolo, Brescia, Catania, Milan, Naples, Rome, Rozzano, Verona

2024-06-07

Recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

NCT06479135Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis

DrugsNavtemadlin·Jakavi·Ruxolitinib

Kartos Therapeutics, Inc.

Phase 3

600

Alessandria, Ancona, Bologna, Brescia, Catania, Florence, Forlì, Milan

2024-06-03

Recruiting

Italian PheNotypes Obstructive Sleep Apnea Study

NCT06872242Sleep Apnea

Istituto Auxologico Italiano

Observational

5,000

Acri, Ancona, Bari, Bergamo, Bologna, Cagliari, Catania, Corigliano-Rossano

2024-06-01

Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06203210Small Cell Lung Cancer

DrugsAmrubicin·Ifinatamab Deruxtecan·Lurbinectedin·Topotecan

Daiichi Sankyo

Phase 3

540

Bari, Bergamo, Brescia, Catania, Catanzaro, Genova, Milan, Monza

2024-05-21

Active, closed

Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

NCT05735834Splenic Marginal Zone Lymphoma

DrugsTruxima·Zanubrutinib·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 3

122

Bari, Bologna, Brescia, Catania, Meldola, Milan, Novara, Palermo

2024-05-21

Active, closed

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841Multiple Myeloma

DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor

AbbVie

Phase 3

421

Legnano, Turin, Rome, Ancona, Catania

2024-05-19

Active, closed

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 3

1,541

Milan, Rozzano, Rome, Bologna, Catania, L’Aquila, Pisa, Vicenza

2024-05-08

Active, closed

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis

DrugNerandomilast

Boehringer Ingelheim

Phase 3

1,666

Brescia, Catania, Florence, Foggia, Forlì, Milan, Modena, Monza

2024-05-06

Active, closed

Extreme Phenotypes to Identify Susceptibility of Patients Living With Type 2 to Diabetes Related Complications

NCT07250607Diabete Type 2, Diabetes Complications

Azienda Ospedaliero, Universitaria Pisana

Observational

1,000

Bari, Catania, Pisa

2024-05-01

Recruiting

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961End Stage Kidney Disease

DrugClazakizumab

CSL Behring

Phase 2/3

3,110

Bologna, Brescia, Cagliari, Caserta, Catania, Ferrara, Florence, Foggia

2024-04-27

Active, closed

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

NCT06372145Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

DrugTeriflunomide

Sanofi

Phase 3

2,500

Pozzilli, Milan, Rome, Florence, Bergamo, Cagliari, Catania, Chieti

2024-04-16

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

Acquaviva delle Fonti, Bari, Bergamo, Brescia, Catania, Catanzaro, Cona, Cortona

2024-04-12

Recruiting

Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

NCT05700149Nodal Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

300

Alessandria, Bari, Bergamo, Brescia, Catania, Cona, Florence, Messina

2024-04-11

Active, closed

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408Sjögren's Syndrome (SS)

DrugDazodalibep

Amgen

Phase 3

434

Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania

2024-04-08

Active, closed

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease

DrugPirfenidone

Avalyn Pharma Inc.

Phase 2

375

Torrette, Naples, Bologna, Venezia, Pavia, Milan, Rozzano, Catania

2024-04-03

Recruiting

A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer

NCT06072781Low Grade Serous Ovarian Cancer

DrugsAvutometinib·Defactinib·Pegylated liposomal doxorubicin·Anastrozole

Verastem, Inc.

Phase 3

270

Aviano, Brescia, Catania, Milan, Naples, Padova, Roma, Rome

2024-03-18

Recruiting

An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program

NCT06782789Diffuse Large B Cell Lymphoma (DLBCL)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

Bologna, Caserta, Catania, Ferrara, Florence, Milan, Novara, Palermo

2024-03-01

Recruiting

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025Solid Cancer

DrugsR-DXd·Topotecan·Paclitaxel

Daiichi Sankyo

Phase 2/3

860

Aviano, Bologna, Catania, Florence, Milan, Monza, Naples, Roma

2024-02-27

Active, closed

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574Lung Cancer, Non-squamous, Non-small Cell

DrugsZongertinib·Pemetrexed·Keytruda·Cisplatin

Boehringer Ingelheim

Phase 3

428

Bari, Candiolo (TO), Catania, Naples, Parma, Roma, Varese

2024-02-09

Active, closed

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744Follicular Lymphoma (FL)

DrugsEpcoritamab·Bendamustine·Obinutuzumab·Vincristine

Genmab

Phase 3

1,095

Rozzano, Candiolo, Bologna, Catania, Palermo, Reggio Emilia, Roma

2024-02-05

Recruiting

Study of Olverembatinib (HQP1351) in Patients With CML-CP

NCT06423911Chronic Myeloid Leukemia, CML, CML, Chronic Phase

DrugsBosutinib·Olverembatinib

Ascentage Pharma Group Inc.

Phase 3

333

Bologna, Candiolo, Catania, Lecce, Meldola, Messina, Milan, Naples

2024-02-05

Active, closed

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06212999Hidradenitis Suppurativa (HS)

DrugPovorcitinib

Incyte Corporation

Phase 3

617

Ancona, Catania, Milan, Pisa, Roma, Rozzano

2024-01-30

Active, closed

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150Multiple Myeloma

DrugsElotuzumab·Talquetamab·Velcade·Teclistamab

Janssen Research & Development, LLC

Phase 3

838

Alessandria, Bologna, Brindisi, Catania, Genova, Legnano, Milan, Pavia

2024-01-22

Active, closed

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

NCT06018337Metastatic Breast Cancer

DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel

DualityBio Inc.

Phase 3

541

Bergamo, Brescia, Catania, Catanzaro, Milan, Pavia, Verona, Naples

2024-01-18

Active, closed

Observational, Prospective Clinical Investigation on Mini 4 Ready Intraocular Lens

NCT06093880Cataract

SIFI SpA

Observational

125

Catania

2024-01-08

Recruiting

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin

Eli Lilly and Company

Phase 3

1,264

Bari, Bologna, Catania, Milan, Naples, Padova, Roma, Rome

2023-12-21

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms

DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Zytiga

Merck Sharp & Dohme LLC

Phase 3

1,314

Meldola, Milan, Catania, Foggia, Terni

2023-12-18

Recruiting

Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation

NCT05955365Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation, P2Y12 Inhibitor

DrugsDOAC·Aspirin

Insel Gruppe AG, University Hospital Bern

Phase 4

3,010

Catania, Milan

2023-12-18

Active, closed

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT06132256Idiopathic Pulmonary Fibrosis

DrugAxatilimab

Syndax Pharmaceuticals

Phase 2

145

Foggia, Milan, Monza, Torino, Padova, Siena, Catania, Florence

2023-12-11

Active, closed

A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760Non-small Cell Lung Cancer

DrugsIntismeran autogene·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

868

Bari, Aviano, Udine, Milan, Naples, Perugia, Catania, Cuneo

2023-12-06

Active, closed

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

NCT05993234HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma

DrugTrastuzumab deruxtecan

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Observational

257

Castellana Grotte, Catania, Florence, Genova, Milan, Modena, Naples, Pisa

2023-12-05

Active, closed

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

NCT06127043Ulcerative Colitis

DrugRosnilimab

AnaptysBio, Inc.

Phase 2

132

Bologna, Cagliari, Catania, Legnano, Milan, Pavia, Rozzano, San Donato

2023-12-04

Active, closed

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NCT06113471NonSegmental Vitiligo

DrugPovorcitinib

Incyte Corporation

Phase 3

450

Brescia, Catania, Milan, Rome, Rozzano

2023-11-27

Recruiting

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

NCT05920356Non-Small Cell Lung Cancer (NSCLC)

DrugsLumakras·Sotorasib·Pembrolizumab

Amgen

Phase 3

750

Bari, Brescia, Candiolo, Catania, Florence, Meldola (FC), Milan, Monza (MB)

2023-11-16

Recruiting

Effect of Phaseolus Vulgaris L. Dry Extract on the Modulation of Weight and Metabolic Parameters

NCT06193577Weight Loss

IBSA Farmaceutici Italia Srl

Not applicable

Catania

2023-11-08

Recruiting

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease

DrugTreprostinil

United Therapeutics

Phase 3

698

Catania, Forlì, Modena, Monza, Roma, Siena, Verona

2023-10-30

Recruiting

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

NCT05879757Multiple Myeloma, Secondary Immunodeficiency (SID)

Takeda

Observational

Bari, Catania, Padova, Treviso

2023-10-17

Recruiting

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240Alopecia Areata

DrugUpadacitinib

AbbVie

Phase 3

1,500

Florence, L’Aquila, Rozzano, Naples, Rome, Bologna, Brescia, Catania

2023-10-11

Active, closed

Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

NCT05941299Mastectomy, Segmental, Breast Neoplasm Malignant Female

Tensive SRL

Not applicable

Rozzano, Catania, Milan, Pavia, Pisa, Roma, Torino

2023-09-29

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

Bari, Bologna, Catania, Florence, Lecco, Milan, Monza, Naples

2023-09-22

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

NCT05816850Follicular Lymphoma

Fondazione Italiana Linfomi - ETS

Observational

654

Alessandria, Biella, Brescia, Catania, Cuneo, Florence, Genova, Meldola

2023-09-19

Active, closed

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

NCT06047080Large B-Cell Lymphoma

DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone

Hoffmann-La Roche

Phase 3

1,130

Naples, Bologna, Modena, Genoa, Bergamo, Milan, Rozzano, Catania

2023-09-18

Recruiting

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic

DrugBelimumab

GlaxoSmithKline

Phase 2/3

300

Roma, Ancona, Bari, Cagliari, Catania, Ferrara, Florence, Milan

2023-09-13

Active, closed

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

NCT06021522Tourette Syndrome

Emalex Biosciences Inc.

Phase 3

150

Genova, Naples, Roma, Catania, Milan

2023-08-16

Active, closed

Acalabrutinib Real World Italian obSErvational Study -ARISE

NCT06205498Chronic Lymphocytic Leukemia

DrugAcalabrutinib

AstraZeneca

Observational

151

Alessandria, Ancona, Bari, Barletta, Brindisi, Campobasso, Catania, Catanzaro

2023-08-08

Recruiting

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

NCT05797831Endometrial Cancer

DrugNavtemadlin

Kartos Therapeutics, Inc.

Phase 2/3

268

Catania, Forlì, Genoa, Lecco, Lucca, Milan, Parma, Piacenza

2023-07-17

Active, closed

A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

NCT05878769Chronic Obstructive Pulmonary Disease

DrugAstegolimab

Hoffmann-La Roche

Phase 3

2,000

Naples, Cona, Ferrara, Pavia, Catania, Palermo

2023-06-28

Active, closed

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

NCT05671510Non Small Cell Lung Cancer

DrugsGotistobart·Taxotere·Docetaxel

OncoC4, Inc.

Phase 3

630

Ancona, Bari, Bergamo, Catania, Milan, Monza, Naples, Palermo

2023-06-28

Active, closed

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016Multiple Myeloma

DrugsIberdomide·Lenalidomide

Bristol-Myers Squibb

Phase 3

1,230

Catania, Florence, Genova, Milan, Pisa, Roma, Torino, Naples

2023-06-22

Recruiting

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

NCT05895786Myositis

Pfizer

Phase 3

318

Rozzano, Roma, Catania, Milan

2023-05-20

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

NCT05748171ACUTE LYMPHOBLASTIC LEUKEMIA

DrugInotuzumab Ozogamicin

Pfizer

Phase 2

100

Naples, Genoa, Monza, Rome, Catania, Padova, Pavia, Torino

2023-05-17

Recruiting

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma

NCT05562466Asthma

DrugBudesonide

Novartis Pharmaceuticals

Phase 3

200

Brescia, Catania, Florence, Pavia, Roma, Naples

2023-05-11

Active, closed

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

NCT05840211Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer

DrugsAbraxane·Xeloda·Sacituzumab Govitecan·Taxol

Gilead Sciences

Phase 3

654

Ancona AN, Aviano, Bergamo, Bologna, Catania, Catanzaro, Genova GE, Milan

2023-05-08

Recruiting

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

NCT06805812Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer, Metastatic, Breast Carcinoma

DrugsAbemaciclib·Ribociclib·Palbociclib

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Observational

3,500

Aviano, Brescia, Catania, Como, Cremona, Florence, Genova, Meldola

2023-05-01

Recruiting

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT06383143AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

760

Bari, Catania, Pavia, Torino

2023-05-01

Recruiting

Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

NCT05817903Metastatic Renal Cell Carcinoma

DrugsAxitinib·Nivolumab

Consorzio Oncotech

Phase 2

118

Brescia, Candiolo, Catania, Cremona, Florence, Genova, Milan, Modena

2023-04-18

Active, closed

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

NCT05757869Atrial Fibrillation

DrugsMilvexian·Apixaban

Janssen Research & Development, LLC

Phase 3

20,284

Arezzo, Aversa, Bergamo, Bologna, Caserta, Catania, Catanzaro, Ferrara

2023-04-11

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

NCT05774951Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

4,300

Bari, Catania, Catanzaro, Florence, Genova, Grosseto, Milan, Modena

2023-03-31

Active, closed

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

NCT05548062Polycythemia Vera

Novartis Pharmaceuticals

Observational

242

Alessandria, Ancona, Bari, Bologna, Como, Cosenza, Catania, Florence

2023-03-02

Active, closed

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642Chronic Obstructive Pulmonary Disease (COPD)

DrugAstegolimab

Hoffmann-La Roche

Phase 3

1,290

Battipaglia, Naples, Ferrara, Pavia, Catania, Palermo

2022-12-29

By invitation

Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II

DrugDeucrictibant

Pharvaris Netherlands B.V.

Phase 2/3

150

Catania, Milan, Naples, Padova, Palermo, Roma

2022-12-28

Recruiting

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

NCT06806579Hepatocellular Carcinoma (HCC)

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Observational

1,000

Torrette, Castellana Grotte, Bologna, Catania, Foggia, Florence, Modena, Milan

2022-12-21

Active, closed

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

NCT05581303Atherosclerotic Cardiovascular Disease

DrugOlpasiran

Amgen

Phase 3

7,297

Arzignano, Bologna, Brescia, Caserta, Catania, Catanzaro, Cona FE, Florence

2022-12-14

Active, closed

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

NCT05668988Non-small Cell Lung Cancer

DrugsSunvozertinib·Pemetrexed·Carboplatin

Dizal Pharmaceuticals

Phase 3

324

Aviano, Bologna, Catania, Florence, Grosseto, Meldola, Modena, Monza

2022-12-13

Recruiting

Quality Of Life On Elderly Patients With Low Grade Non-Hodgkin Lymphoma

NCT05524298Low Grade Non-Hodgkin's Lymphoma, Adult

Fondazione Italiana Linfomi - ETS

Observational

150

Alessandria, Ancona, Bari, Brescia, Castelfranco Veneto, Catania, Florence, Messina

2022-12-07

Recruiting

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

NCT06894173Breast Cancer

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Observational

1,000

Aviano, Ancona, Avellino, Brindisi, Catania, Genova, Mantua, Meldola

2022-12-03

Recruiting

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

NCT05924100Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia

DrugsReblozyl·Luspatercept

Associazione Qol-one

Phase 2

Alessandria, Ancona, Avellino, Biella, Catania, Chivasso, Cosenza, Florence

2022-11-03

Active, closed

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

NCT05567796Obesity

DrugsCagrilintide·Semaglutide

Novo Nordisk A/S

Phase 3

3,400

Bari, Catanzaro, San Donato Milanese (MI), Roma, Siena, Bologna, Catania, Padova

2022-11-01

Recruiting

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

NCT05363319Non-small Cell Lung Cancer

DrugCemiplimab

Regeneron Pharmaceuticals

Observational

500

Misterbianco, Florence, Udine, Rozzano, Orbassano, Pisa, Catania, Milan

2022-10-26

Active, closed

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320Multiple Myeloma

DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone

Janssen Research & Development, LLC

Phase 3

864

Ancona, Bari, Bologna, Brescia, Catania, Milan, Padova, Palermo

2022-10-13

Active, closed

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

NCT05306301Chemotherapy, Leukemia, Acute Lymphoblastic

DrugPonatinib

Gruppo Italiano Malattie EMatologiche dell'Adulto

Phase 2

Avellino, Pagani, Bergamo, Bologna, Brescia, Catania, Florence, Lecce

2022-10-05

Recruiting

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

201

Catania, Genova, Milan, Naples, Orbassano, Pavia, Roma, Rozzano

2022-09-23

Recruiting

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05519085Relapsed or Refractory Multiple Myeloma

DrugsMezigdomide·Velcade·Pomalidomide·Bortezomib

Celgene

Phase 3

810

Meldola, Rome, Catania, Bologna, Pavia

2022-09-20

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT05242484Colitis, Ulcerative

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

577

Bari, Catania, Messina, Milan, Monserrato, Monza, Negrar, Palermo

2022-09-19

Active, closed

Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

NCT05570058IPF, Fibrosis

Redx Pharma Ltd

Phase 2

Ancona, Catania, Foggia, Lecce, Milan, Modena, Roma, Verona

2022-09-08

Recruiting

Evaluation of Inflammatory Markers in ph Negative Myeloproliferative Neoplasms: Impact on Outcome and Response to Therapy. Multicenter Retro-prospective Observational Study. The INFLA-ME (INFLAmmation in Myeloproliferative Disease) Study.

NCT05553873Myeloproliferative Disease, Inflammatory Markers

University of Milano Bicocca

Observational

500

Bari, Bologna, Brescia, Catania, Naples, Roma, Torino, Udine

2022-09-08

Recruiting

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368Hypereosinophilic Syndrome

DrugDepemokimab

GlaxoSmithKline

Phase 3

109

Bologna, Catania, Milan, Naples, Novara, Pavia, Roma, Treviso

2022-09-06

By invitation

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

DrugTreprostinil

United Therapeutics

Phase 3

1,850

Modena, Rome, Milan, Catania, Siena, Ancona, Forlì, Roma

2022-09-06

Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

NCT05548296Endometrial Adenocarcinoma

DrugGemcitabine

Acrivon Therapeutics

Phase 2

350

Aviano, Catania, Milan, Naples, Pieve Emanuele, Roma, Turin

2022-08-29

Active, closed

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578Dermatitis Atopic

DrugAmlitelimab

Sanofi

Phase 2/3

1,856

Milan, Rozzano, Naples, Rome, Turin, Bologna, Catania, Chieti

2022-08-22

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Avellino, Aviano, Catania, Meldola, Milan, Modena, Monserrato, Naples

2022-08-03

Active, closed

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

NCT05242471Crohn's Disease

DrugsJNJ-78934804·Golimumab·Guselkumab

Janssen Research & Development, LLC

Phase 2

703

Bari, Catania, Messina, Milan, Monopoli, Monserrato, Monza, Negrar ( Ve)

2022-07-22

Active, closed

A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)

NCT05392114Hereditary Angioedema

DrugDonidalorsen

Ionis Pharmaceuticals, Inc.

Phase 3

154

Catania, Naples, Padova, Palermo, San Donato Milanese

2022-07-13

Active, closed

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms

DrugsNab-paclitaxel /m^2·Relacorilant

Corcept Therapeutics

Phase 3

381

Catania, Legnago, Milan, Pavia, Roma, Rome, Torino, Treviso

2022-06-29

Active, closed

(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis

NCT05186753SSM, Mastocytosis, Indolent, Mastocytosis, Systemic, Mastocytosis

DrugBezuclastinib

Cogent Biosciences, Inc.

Phase 2

237

Bologna, Catania, Florence, Pavia, Ravenna

2022-06-27

Active, closed

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04975997Multiple Myeloma

DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone

Celgene

Phase 3

939

Rome, Bologna, Catania, Genova, Milan, Novara, Pavia, Pisa

2022-06-23

Recruiting

Effects of Confortable Environment, Kangaroo Care and Music Therapy in Newborns in Neonatal Intensive Care Unit

NCT06256406Premature Infant Disease, Newborn Morbidity

Policlinico Universitario, Catania

Not applicable

Catania

2022-06-20

Active, closed

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

NCT05186974Non-small Cell Lung Cancer

DrugsSacituzumab Govitecan·Paraplatin·Keytruda·Cisplatin

Gilead Sciences

Phase 2

193

Brescia, Catania, Parma, Rome, Rozzano

2022-05-30

Active, closed

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

NCT05123703Relapsing-remitting Multiple Sclerosis

DrugsFingolimod·Ocrelizumab

Hoffmann-La Roche

Phase 3

188

Chieti, Bari, Rome, Milan, Catania

2022-05-19

Active, closed

Evolut™ EXPAND TAVR II Pivotal Trial

NCT05149755Moderate Aortic Valve Stenosis

Medtronic Cardiovascular

Not applicable

650

Catania, Milan, San Donato Milanese

2022-04-27

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Arezzo, Bari, Catania, Meldola, Milan, Modena, Padova, Pisa

2022-04-19

Active, closed

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

NCT05317416Multiple Myeloma

DrugsElranatamab·Lenalidomide

Pfizer

Phase 3

854

Meldola, Rome, Milan, Catania, Siena, Ancona, Bologna, Roma

2022-03-25

Active, closed

A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors

NCT05135559Haemophilia A and B With and Without Inhibitors

DrugConcizumab

Novo Nordisk A/S

Phase 3

153

Catania, Florence, Padova, Parma

2022-03-24

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Bari, Catania, Florence, Genova, Milan, Naples, Padova, Parma

2022-02-21

Active, closed

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

NCT05002127Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma

DrugsEvorpacept·Ramucirumab·Herceptin·Taxol

ALX Oncology Inc.

Phase 2/3

127

Catania, Florence, Milan, Roma, Udine

2022-01-15

Active, closed

LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm Treatment

NCT04999423Intracranial Aneurysm

Microvention-Terumo, Inc.

Observational

206

Catania, Messina, Salerno

2022-01-14

Recruiting

Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)

NCT04996017Mesotheliomas Pleural

DrugAtezolizumab

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 3

162

Meldola, Alessandria, Bari, Catania, Chieti, Ferrara, Genova, Mestre

2021-12-14

Recruiting

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT04910685Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis

Blueprint Medicines Corporation

Phase 2/3

534

Milan, Florence, Bologna, Catania, Pavia, Salerno, Verona, Vicenza

2021-11-30

Recruiting

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584Relapsed/Refractory Multiple Myeloma

Janssen Pharmaceutica N.V., Belgium

Observational

300

Bari, Bologna, Catania, Civitanova Marche, Genova, Lecce, Meldola, Padova

2021-11-18

Active, closed

A Study to Assess Real-World Use, Safety, and Effectiveness of Oral Upadacitinib in Adult and Adolescent (>=12 Years Old) Participants With Atopic Dermatitis

NCT05081557Atopic Dermatitis

AbbVie

Observational

873

Bari, Catania, Genoa, Messina, Milan, Turin, Roma, Cava de' Tirreni

2021-11-17

Active, closed

Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT05089734Non-Small Cell Lung Cancer

DrugsSacituzumab Govitecan·Docetaxel

Gilead Sciences

Phase 3

603

Bergamo, Brescia, Catania, Catanzaro, Cremona, Milan, Pavia, Roma

2021-11-17

Recruiting

A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

NCT05020236Multiple Myeloma

DrugsDarzalex·Elranatamab·Pomalidomide·Daratumumab

Pfizer

Phase 3

893

Meldola, Milan, Monza, Catania, Bologna, Genova, Roma

2021-10-04

Active, closed

A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate

NCT04909801Rheumatoid Arthritis

DrugsAbatacept·Humira·Adalimumab·Methotrexate

Bristol-Myers Squibb

Phase 3

338

Catania, Pavia, Perugia, Roma

2021-09-15

Active, closed

Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786Advanced Breast Cancer

DrugsAlpelisib·Herceptin·Eribulin·Vinorelbine

Spanish Breast Cancer Research Group

Phase 3

Alessandria, Ancona, Bolzano, Castellanza, Catania, Cremona, Florence, Genoa

2021-09-14

Active, closed

Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC

NCT04919811Non Small Cell Lung Cancer

DrugTaletrectinib

Nuvation Bio Inc.

Phase 2

217

Bari, Catania, Milan, Monserrato, Naples, Roma

2021-09-01

By invitation

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction

NCT04957719Acute Myocardial Infarction

Viatris Innovation GmbH

Phase 3

25,000

Arezzo, Bologna, Caserta, Catania, Catanzaro, Cona, Florence, Messina

2021-08-14

Active, closed

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

NCT04959448Chronic Rhinosinusitis With Nasal Polyposis

DrugDupilumab

Regeneron Pharmaceuticals

Observational

717

Rozzano, Catania, Pisa, Siena, Padova, Catanzaro, Genova, Rome

2021-08-12

Recruiting

Observational Study in Localized Osteosarcoma

NCT04890067Localized Osteosarcoma

Italian Sarcoma Group

Observational

120

Aviano, Candiolo, Trieste, Bari, Bologna, Catania, Florence, Genova

2021-07-30

By invitation

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

NCT04976322Systemic Lupus Erythematosus

UCB Biopharma SRL

Phase 3

760

Catania, Milan

2021-07-27

Active, closed

CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen

NCT05312398Metastatic Colorectal Adenocarcinoma

DrugsErbitux·Folfox·Cetuximab·Irinotecan

University of Campania Luigi Vanvitelli

Phase 2

219

Ancona, Acquaviva delle Fonti, Bari, Castellana Grotte, Benevento, Brindisi, Monserrato, Catania

2021-07-15

Recruiting

A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis

NCT04951622Myasthenia Gravis

DrugNipocalimab

Janssen Research & Development, LLC

Phase 3

199

Catania, Cefalù, Milan, Naples, Pavia, Roma

2021-07-15

Recruiting

Health-care Quality in Semi-intensive Care Units

NCT04676347Semi-intensive Care Unit, Evaluation, Quality

Mario Negri Institute for Pharmacological Research

Observational

39,000

Milan, Alessandria, Bassano del Grappa, Bologna, Catania, Cesena, Livorno, Lodi

2021-07-01

Active, closed

Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

NCT04915755Neoplasms, Breast

DrugNiraparib

GlaxoSmithKline

Phase 3

Ancona, Bologna, Brindisi, Candiolo to, Catania, Genova, Meldola FC, Milan

2021-06-28

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Ancona, Bergamo, Catania, Milan, Naples, Padova, Prato

2021-06-22

Active, closed

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

NCT04895358Breast Neoplasms

DrugsLiposomal doxorubicin·Abraxane·Xeloda·Taxol

Merck Sharp & Dohme LLC

Phase 3

342

Rome, Milan, Monza, Rozzano, Bari, Catania, Naples, Padova

2021-06-18

Active, closed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis

NCT04882098Arthritis, Psoriatic

DrugGuselkumab

Janssen Research & Development, LLC

Phase 3

1,054

Catania, Milan, Naples, Palermo, Rome, Torino, Verona

2021-06-17

By invitation

ManAgement of pRiapiSm and Its Impact on Outcomes

NCT04932902Priapism

Policlinic Hospital "G. Rodolico"

Observational

200

Catania, Florence, Torino, Varese

2021-06-01

Active, closed

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

NCT05015010Non Small Cell Lung Cancer

DrugAlectinib

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2

Meldola, Lido di Camaiore, Monza, Aviano, Orbassano, Bari, Bologna, Catania

2021-05-20

Active, closed

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

NCT04824092Diffuse Large B-cell Lymphoma

DrugsTafasitamab·Vincristine·Doxorubicin·Prednisone

Incyte Corporation

Phase 3

899

Bergamo, Brescia, Candiolo, Catania, Forlì, Genoa, Lecce, Milan

2021-05-11

Active, closed

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

NCT04871919Rheumatoid Arthritis

DrugFilgotinib

Alfasigma S.p.A.

Observational

1,304

Bari, Brescia, Catania, Ferrara, Genova, Milan, Naples, Roma

2021-05-11

Active, closed

Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

NCT04700124Bladder Cancer

DrugsEnfortumab Vedotin·Keytruda·Gemcitabine·Cisplatin

Merck Sharp & Dohme LLC

Phase 3

808

Milan, Pozzuoli, Orbassano, Verona, Ancona, Catania, Padova

2021-04-21

Active, closed

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

NCT04680052Follicular Lymphoma, Marginal Zone Lymphoma

DrugsTafasitamab·Lenalidomide·Rituximab

Incyte Corporation

Phase 3

654

Bari, Brescia, Candiolo, Catania, Lecce, Milan, Naples, Novara

2021-04-15

Active, closed

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586010Relapsing Multiple Sclerosis

DrugsFenebrutinib·Teriflunomide

Hoffmann-La Roche

Phase 3

746

Foggia, Naples, Parma, Rome, Bergamo, Milan, Mondovì (CN), Catania

2021-03-17

Recruiting

A "Physician & Patient-powered" Cohort Registry (MY MYELOMA)

NCT05001087Multiple Myeloma

Fondazione EMN Italy Onlus

Observational

1,900

Florence, Ancona, Bari, Bologna, Brescia, Catania, Genova, Milan

2021-03-16

Active, closed

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389Myelofibrosis

DrugsSelinexor·Ruxolitinib

Karyopharm Therapeutics Inc

Phase 3

353

Catania, Meldola, Genova, Milan, Monza, Novara, Rionero in Vulture, Roma

2021-03-11

Active, closed

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

NCT04608318Chronic Lymphoid Leukemia

DrugsVenclyxto·Ibrutinib·Obinutuzumab·Venetoclax

German CLL Study Group

Phase 3

897

Catania, Ferrara, Mestre, Milan, Perugia, Roma, Torino

2021-03-01

Active, closed

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis

DrugLuspatercept

Celgene

Phase 3

313

Meldola (fc), Ancona, Bologna, Brescia, Catania, Florence, Milan, Napoli Campania

2021-02-25

Active, closed

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer

DrugsAdagrasib·Taxotere·Docetaxel

Mirati Therapeutics Inc.

Phase 3

453

Alessandria, Avellino, Aviano, Bari, Brescia, Candiolo, Catania, Florence

2021-02-23

Active, closed

A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)

NCT04624659Sickle Cell Disease

DrugEtavopivat

Forma Therapeutics, Inc.

Phase 3

450

Pavia, Catania, Orbassano, Padova, Palermo, Roma

2021-01-29

Active, closed

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

NCT04204616Prurigo Nodularis

DrugNemolizumab

Galderma R&D

Phase 3

500

Catania, Chieti, Genova, L’Aquila, Modena, Naples, Parma, Perugia

2021-01-11

Active, closed

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

NCT04521231B Cell Precursor Acute Lymphoblastic Leukemia

DrugBlinatumomab

Amgen

Phase 1/2

181

Bergamo, Bologna, Brescia, Catania, Milan, Naples, Roma

2021-01-04

Active, closed

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

NCT04656652Non-small Cell Lung Cancer

DrugsDato-DXd·Docetaxel

Daiichi Sankyo

Phase 3

605

Bologna, Catania, Genova, Milan, Orbassano, Roma

2020-12-21

Active, closed

ACURATE neo2™ Post Market Clinical Follow up Study

NCT04655248Aortic Valve Stenosis, Aortic Valve Calcification, Aortic Diseases

Boston Scientific Corporation

Observational

250

Catania, Milan, Pisa

2020-12-16

Active, closed

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

NCT04658862Urinary Bladder Neoplasms

DrugsTAR-200·Cetrelimab·Gemcitabine·Cisplatin

Janssen Research & Development, LLC

Phase 3

518

Arezzo, Candiolo, Carpi, Catania, Foggia, Genova, Lugo, Milan

2020-12-07

Active, closed

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

DrugsTrastuzumab emtansine·Trastuzumab deruxtecan

Daiichi Sankyo

Phase 3

1,600

Catania, Milan, Ancona, Aviano, Bari, Belluno, Bologna, Brindisi

2020-12-04

Active, closed

FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

NCT04333524Marginal Zone Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Observational

496

Alessandria, Ponderano, Cagliari, Catania, Milan, Palermo, Padova, Pescara

2020-12-01

Recruiting

LANDMARK Trial: a Randomised Controlled Trial of Myval THV

NCT04275726Aortic Valve Stenosis

Meril Life Sciences Pvt. Ltd.

Not applicable

988

Bologna, Catania, Milan, Tortona, Turin

2020-11-04

Active, closed

A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions

NCT04538664Carcinoma, Non-Small-Cell Lung

DrugsAmivantamab·Pemetrexed·Carboplatin

Janssen Research & Development, LLC

Phase 3

308

Bologna, Catania, Meldola, Milan, Monza, Ravenna, Roma, Rozzano

2020-10-13

Recruiting

Impact of Non-surgical Periodontal Therapy in the Improvement of Early Endothelial Dysfunction in Subjects With Peri-implantitis and Peri-implant Mucositis

NCT05906810Atherosclerosis, Endothelial Dysfunction, Peri-Implantitis, Peri-implant Mucositis

University of Catania

Not applicable

Catania

2020-10-05

Active, closed

A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04487080Carcinoma, Non-Small-Cell Lung

DrugsLazertinib·Amivantamab·Osimertinib

Janssen Research & Development, LLC

Phase 3

1,074

Avellino, Catania, Meldola, Milan, Monza, Naples, Orbassano, Ravenna

2020-09-30

Recruiting

AutoInflammatory Disease Alliance Registry (AIDA)

NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome

University of Siena

Observational

3,500

Siena, Bari, Bolzano, Brescia, Cagliari, Catania, Catanzaro, Chieti

2020-08-06

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Ancona, Bologna, Brescia, Candiolo, Catania, Lecce, Lecco, Milan

2020-08-04

Active, closed

Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

NCT04282811Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia

DrugVenetoclax

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

321

Cona, Alessandria, Bari, Cagliari, Catania, Catanzaro, Cosenza, Florence

2020-07-24

Recruiting

Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib

NCT03651206Ovarian Carcinosarcoma, Endometrial Carcinosarcoma

DrugNiraparib

ARCAGY/ GINECO GROUP

Phase 2/3

138

Bologna, Catania, Meldola, Milan, Naples, Roma, Torino

2020-07-15

Active, closed

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

DrugTazemetostat

Epizyme, Inc.

Phase 3

599

Naples, Meldola, Brescia, Catania, Florence, Lecce, Milan, Monza

2020-06-11

Active, closed

Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)

NCT03896074Non-small-cell Lung Cancer Patients

DrugsAtezolizumab·Bevacizumab

Fondazione Ricerca Traslazionale

Phase 2

206

Ponderano, Lecco, Catania, Grosseto, Province of Macerata, Monza, Modena, Piacenza

2020-03-02

Active, closed

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

NCT04199689Papillomavirus Infections

DrugNonavalent HPV vaccine

Merck Sharp & Dohme LLC

Phase 3

6,033

Rome, Padova, Bari, Catania, Roma

2020-02-27

Active, closed

A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer

NCT04211337Medullary Thyroid Cancer

DrugsVandetanib·Selpercatinib·Cabozantinib

Loxo Oncology, Inc.

Phase 3

291

Naples, Rome, Milan, Turin, Pisa, Siena, Padova, Catania

2020-02-11

Active, closed

MitraClip EXPAND G4 Study

NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation

Abbott Medical Devices

Observational

1,164

Milan, Catania

2020-01-17

Active, closed

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

NCT04075266Multiple Sclerosis

DrugOcrelizumab

Hoffmann-La Roche

Phase 2

Rome, Catania

2020-01-09

Recruiting

Terumo Aortic Global Endovascular Registry

NCT04246463Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Surgery

Vascutek Ltd.

Observational

1,000

Bari, Bolzano, Cagliari, Careggi, Catania, Modena, Siena, Turin

2019-12-17

Recruiting

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

NCT04221035High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy

DrugsDinutuximab Beta·Vindesine·Cyclophosphamid·Thiotepa

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3

800

Bari, Brescia, Catania, Florence, Genova, Modena, Parma, Pavia

2019-11-05

Recruiting

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

NCT04793919Acute Promyelocytic Leukemia

DrugsMylotarg·All-trans retinoic acid·Arsenic Trioxide·ATRA

Associazione Italiana Ematologia Oncologia Pediatrica

Phase 2

San Giovanni Rotondo, Bari, Bergamo, Bologna, Cagliari, Catania, Florence, Genova

2019-10-09

Recruiting

International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

NCT04043494Lymphoblastic Lymphoma, Childhood

DrugsVindesine·Thioguanine·PEG-Asparaginase·Ifosfamide

University Hospital Muenster

Phase 3

683

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Cona

2019-08-23

Active, closed

Observational Evaluation of Atopic Dermatitis in Pediatric Patients

NCT03687359Dermatitis Atopic

Sanofi

Observational

1,860

Terracina, Naples, Padua, Bari, Bologna, Brescia, Catania, Milan

2019-08-15

Active, closed

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050Warm Autoimmune Hemolytic Anemia

DrugNipocalimab

Janssen Research & Development, LLC

Phase 2/3

118

Ascoli Piceno, Brescia, Catania, Florence, Milan, Monza, Novara, Roma

2019-08-15

Recruiting

Pan Tumor Rollover Study

NCT03899155Cancer

DrugsRucaparib·Sunitinib·Trametinib·Relatlimab

Bristol-Myers Squibb

Phase 2

1,500

Meldola, Rozzano, Roma, Bari, Bergamo, Candiolo, Catania, Genova

2019-08-09

Active, closed

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

NCT04008030Metastatic Colorectal Cancer

DrugsFluorouracil·Leucovorin·Ipilimumab·Cetuximab

Bristol-Myers Squibb

Phase 3

839

Catania, Genova, Milan, Naples, Padova, Roma

2019-08-05

Active, closed

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

NCT03924895Urinary Bladder Cancer, Muscle-invasive

DrugsEnfortumab Vedotin·Keytruda·Pembrolizumab

Merck Sharp & Dohme LLC

Phase 3

595

Roma, Orbassano, Vicenza, Arezzo, Catania, Milan, Naples, Pavia

2019-07-24

Active, closed

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

NCT03974022Non-Small Cell Lung Cancer

DrugSunvozertinib

Dizal Pharmaceuticals

Phase 1/2

315

Aviano, Catania, Florence, Meldola, Milan, Parma, Ravenna, Reggio Emilia

2019-07-09

Active, closed

A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients

NCT04124497Multiple Myeloma, Deletion 17P Syndrome

DrugsDarzalex·Pomalidomide·Daratumumab·Dexamethasone

Fondazione EMN Italy Onlus

Phase 2

Ancona, Bari, Bergamo, Bologna, Brescia, Catania, Milan, Novara

2019-07-01

Active, closed

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772Non-Small Cell Lung Cancer

DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib

AstraZeneca

Phase 2

247

Catania, Naples, Orbassano, Padova, Varese

2019-06-25

Active, closed

Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

NCT03896737Multiple Myeloma

DrugDaratumumab

European Myeloma Network B.V.

Phase 2

401

Ancona, Bergamo, Bologna, Brescia, Catania, Genova, Milan, Novara

2019-04-16

Active, closed

Acute Normovolemic Hemodilution in High Risk Cardiac Surgery Patients.

NCT03913481C.Surgical Procedure; Cardiac

Università Vita-Salute San Raffaele

Not applicable

2,000

Cotignola, Catania, Lecce, Milan, Padua, Pisa, Potenza, Rome

2019-04-15

Active, closed

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

NCT03675308Psoriatic Arthritis

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

964

Modena, Ancona, Catania, Rome, Verona

2019-03-25

Active, closed

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy

NCT03762850Immunoglobulin A Nephropathy

DrugsSparsentan·Irbesartan·Dapagliflozin

Travere Therapeutics, Inc.

Phase 3

406

Ranica, Milan, Bari, Catania, Catanzaro, Lecco, Modena, Pavia

2018-12-11

Active, closed

National Register of Actionable Mutations

NCT05918666Solid Tumours in Advanced Stages

Federation of Italian Cooperative Oncology Groups

Observational

2,098

Ancona, Arezzo, Avellino, Aviano, Bari, Bergamo, Brindisi, Catania

2018-10-27

Active, closed

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388Differentiated Thyroid Cancer

DrugCabozantinib

Exelixis

Phase 3

187

Viagrande, Catania, Meldola, Genova, Rozzano, Pisa, Torino, Milan

2018-10-05

Active, closed

A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis

NCT03398135Ulcerative Colitis (UC)

DrugsSkyrizi·Risankizumab

AbbVie

Phase 3

1,242

Genoa, Rozzano, Milan, Rho, Rome, Negrar, Bologna, Catania

2018-08-28

Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

NCT03486873Solid Tumors, Hematologic Malignancies

DrugsPembrolizumab/Favezelimab·) Berahyaluronidase alfa·Olaparib·Lenvatinib

Merck Sharp & Dohme LLC

Phase 3

3,500

Bologna, Rome, Milan, Monza, Rozzano, Aviano, Catania, Candiolo

2018-08-21

Active, closed

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318Atopic Dermatitis

DrugUpadacitinib

AbbVie

Phase 3

1,533

Rome, Rozzano, Ancona, Catania, Milan, Naples

2018-08-09

Recruiting

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

NCT03592472Renal Cell Carcinoma

DrugsAbexinostat·Pazopanib

Xynomic Pharmaceuticals, Inc.

Phase 3

413

Candiolo, Catania, Meldola (FC), Milan, Naples, Novara, Pavia, Pisa

2018-07-17

Recruiting

Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

NCT03643276Acute Lymphoblastic Leukemia, Pediatric

DrugsFludarabine Phosphate·Vindesine·Tioguanin·Erwinase

Martin Schrappe

Phase 3

5,000

Ancona, Bari, Bergamo, Bologna, Brescia, Cagliari, Catania, Catanzaro

2018-07-15

Active, closed

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

NCT03522246Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed

DrugsRucaparib·Opdivo·Nivolumab

pharmaand GmbH

Phase 3

1,097

Aviano, Candiolo, Catania, Chieti, Naples, Roma, Vicenza

2018-05-14

Active, closed

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

NCT03473743Urothelial Carcinoma

DrugsErdafitinib·Cetrelimab·Cisplatin·Carboplatin

Janssen Research & Development, LLC

Phase 1/2

125

Bergamo, Candiolo, Carpi, Catania, Ferrara, Lecco, Livorno, Milan

2018-04-05

Active, closed

A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)

NCT03246529Multiple Myeloma

DrugsMotixafortide·G-Csf

BioLineRx, Ltd.

Phase 3

180

Catania, Reggio Calabria

2018-03-23

Active, closed

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

NCT03345823Crohn's Disease

DrugUpadacitinib

AbbVie

Phase 3

747

Bologna, Rozzano, Milan, Rome, Negrar, Catania, Catanzaro, Genova

2018-03-21

Recruiting

Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978Haemophilia A

Octapharma

Observational

200

Bari, Bologna, Castelfranco Veneto, Catania, Florence, Milan, Padova, Rome

2018-02-13

Active, closed

Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

NCT03261206Crohn Disease, Remission

Alimentiv Inc.

Phase 4

334

San Donato Milanese, Milan, Roma, Castellana Grotte, Catania, Padova

2017-11-20

Active, closed

Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma

NCT03190525Multiple Myeloma

Gruppo Italiano Malattie EMatologiche dell'Adulto

Observational

530

Ancona, Bologna, Brindisi, Cagliari, Catania, Catanzaro, Cona, Cosenza

2017-11-13

Active, closed

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

NCT03052608Carcinoma, Non-Small-Cell Lung

DrugsCrizotinib·Lorlatinib

Pfizer

Phase 3

296

Catania, Monza, Milan, Rozzano, Perugia, Pordenone, Parma, Roma

2017-04-27

Active, closed

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

NCT01896479Medullary Thyroid Cancer

Exelixis

Phase 4

247

Catania, Roma, Siena, Pisa, Milan, Padua, Torino

2015-02-25

Active, closed

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

NCT02152631Non Small Cell Lung Cancer

DrugsErlotinib·Abemaciclib

Eli Lilly and Company

Phase 3

453

Catania, Genova, Livorno, Parma, Rome

2014-10-03

Recruiting

Arrhythmias Detection in a Real World Population

NCT02275637Appropriate and Inappropriate Shock Therapy With ICD, Arrhythmias Detection

Fondazione IRCCS Policlinico San Matteo di Pavia

Observational

10,000

Bergamo, Bologna, Catania, Florence, Milan, Naples, Padua, Pavia

2014-09

Active, closed

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599MALT Lymphoma

DrugsChlorambucil·Rituximab

International Extranodal Lymphoma Study Group (IELSG)

Phase 2

112

Alessandria, Ancona, Aviano, Biella, Bolzano, Cagliari, Catania, Genova

2013-12

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

DrugOlaparib

AstraZeneca

Phase 3

450

Bari, Catania, Milan, Naples, Padova, Roma

2013-08-26

Active, closed

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

NCT01892722Multiple Sclerosis

DrugsAvonex·Fingolimod

Novartis Pharmaceuticals

Phase 3

240

Bari, Montichiari, Catania, Milan, Cefalù, Roma, Gallarate

2013-07-26

Active, closed

Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank

NCT02951416Idiopathic Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Interstitial Lung Diseases, Diffuse Parenchymal Lung Diseases

Andreas Guenther

Observational

2,000

Catania

2009-09

Recruiting

Exactech Shoulder Post Market Clinical Follow-up Study

NCT05603728Osteo Arthritis Shoulders, Osteonecrosis, Rotator Cuff Tears, Rotator Cuff Tear Arthropathy

Exactech

Observational

20,000

Catania, Eboli

2007-07-19

Recruiting

International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

NCT00358943Gaucher Disease, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease

Genzyme, a Sanofi Company

Observational

12,000

Florence, Milan, Baggiovara, Monza, Rome, Sassari, Catania, Genova

1991-04-01

Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/catania

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 343 of those studies with a site in Catania.

How many clinical trials are recruiting in Catania?

169 of the 343 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 12 have not yet opened recruitment, 149 are active but closed to new participants, and 13 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Catania), 343 studies
Phase	Studies	Recruiting	Share
Phase 3	165	70	48.1%
Observational	87	55	25.4%
Phase 2	48	19	14%
Not applicable	18	12	5.2%
Phase 2/3	15	9	4.4%
Phase 4	6	3	1.7%
Phase 1/2	4	1	1.2%

Most active sponsors

Lead sponsors with the most studies (Catania)
Lead sponsor	Studies	Recruiting
AstraZeneca	22	13
Janssen Research & Development, LLC	18	7
Incyte Corporation	13	5
Merck Sharp & Dohme LLC	11	4
AbbVie	10	3
Fondazione Italiana Linfomi - ETS	8	5
GlaxoSmithKline	8	7
Pfizer	8	4
University of Catania	8	4
Daiichi Sankyo	7	4

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.